Skip to content

Role of Kampillakadi Yoga and Tab Metformin in Diabetes Mellitus Type 2 vis-a-vis Prameha

A comparative clinical evaluation of kampillakadi yoga and metformin in the patients of type 2 diabetes Mellitus vis a vis madhumeha - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/01/079194
Enrollment
70
Registered
2025-01-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

Department of Kayachikitsa Faculty of ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age between 30 to 60 years Newly diagnosed patient and patient having chronicity less than 3years. Patient Body weight- normal to obese. (BMI18.5 to 34.9) Patient having no family history of DM Patient having Fasting blood sugar 126 mg/dl to 200 mg/dl Patient having Post prandial blood sugar more than 200mg/dl to 300mg/dl Patient having HbA1c more than 6.5% to 10% Patient fulfilling the diagnostic criteria of American Diabetes Association and as mentioned In Ayurvedic text.

Exclusion criteria

Exclusion criteria: Age less than 30 to more than 60 years Patients having chronicity more than 3years Moderately to grossly obese patients (BMI more than 35) Type 1 diabetes. Patient having Fasting blood sugar more than 200mg/dl Patient having Post prandial blood sugar more than 300mg/dl Patient having HbA1c more than 10% Patients on medications other than Metformin Patients on insulin therapy Severe heart liver lung kidney disease or incurable Cancer with complication of diabetes mellitus discussed earlier.

Design outcomes

Primary

MeasureTime frame
polyuria turbid urine polydepsia polyphagia burning sensation in hand and feet perspiration dryness of palate and throat feeling sweetness in mouth Numbness Fatiguibility Timepoint: 90 days with follow up interval at 30 days interval.

Secondary

MeasureTime frame
1Quality of life QOL-BREF 2Assessement of severity of agni 3assessment into 0-3 scale on the basis of severity and duration of DM. 4hematological investigations (FBS PPBS HbA1c CRP Lipid profile RFT LFT)Timepoint: FBS and PPBS at every follow up of 30 days and other hematological tests at day 0 and day 90 .

Countries

India

Contacts

Public ContactDrAjai Kumar Pandey

Banaras Hindu University

drajaipandey@gmail.com9452827885

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026